Informações:
Falhas:
ID
29136
Descrição
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00692237
Link
https://clinicaltrials.gov/show/NCT00692237
Palavras-chave
Versões (1)
- 28/02/2018 28/02/2018 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
28 de fevereiro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Diabetes Mellitus, Type 2 NCT00692237
Eligibility Diabetes Mellitus, Type 2 NCT00692237
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT00692237
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Diabetes Mellitus, Non-Insulin-Dependent
Item
patients with type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Age
Item
patients age 35-75
boolean
C0001779 (UMLS CUI [1])
Metabolic Control Diabetes | Diet therapy unchanged | Oral medication Therapeutic procedure unchanged
Item
metabolic control of diabetes by diet or oral treatment (unmodified in the last 3 months)
boolean
C1513158 (UMLS CUI [1,1])
C0011847 (UMLS CUI [1,2])
C0012159 (UMLS CUI [2,1])
C0442739 (UMLS CUI [2,2])
C0175795 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0442739 (UMLS CUI [3,3])
C0011847 (UMLS CUI [1,2])
C0012159 (UMLS CUI [2,1])
C0442739 (UMLS CUI [2,2])
C0175795 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0442739 (UMLS CUI [3,3])
Blood pressure determination | Hypertension controlled | Angiotensin-Converting Enzyme Inhibitors unchanged | Selective Angiotensin II Receptor Antagonists unchanged
Item
blood pressure <160/100 mmhg, including subjects with controlled hypertension, treated with ace-inhibitors/sartans, unmodified in the last 3 months
boolean
C0005824 (UMLS CUI [1])
C0745117 (UMLS CUI [2])
C0003015 (UMLS CUI [3,1])
C0442739 (UMLS CUI [3,2])
C1563745 (UMLS CUI [4,1])
C0442739 (UMLS CUI [4,2])
C0745117 (UMLS CUI [2])
C0003015 (UMLS CUI [3,1])
C0442739 (UMLS CUI [3,2])
C1563745 (UMLS CUI [4,1])
C0442739 (UMLS CUI [4,2])
Study Subject Participation Status | Investigational New Drugs | Investigational Medical Device
Item
participation in another study with an investigational drug or device
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C2346570 (UMLS CUI [3])
C0013230 (UMLS CUI [2])
C2346570 (UMLS CUI [3])
Glucohemoglobin measurement
Item
hba1c >12%
boolean
C0202054 (UMLS CUI [1])
Exercise stress ECG test Alteration
Item
alterations during ecg stress examination
boolean
C1304755 (UMLS CUI [1,1])
C1515926 (UMLS CUI [1,2])
C1515926 (UMLS CUI [1,2])
Nitrate agent
Item
current use of nitrate agents
boolean
C0459106 (UMLS CUI [1])
Proliferative retinopathy
Item
proliferative retinopathy
boolean
C0339467 (UMLS CUI [1])
Cardiovascular Diseases | Malignant Neoplasms
Item
patients with history of cardiovascular and malignant disease
boolean
C0007222 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
C0006826 (UMLS CUI [2])
Psychosocial problem
Item
psychosocial disturbance
boolean
C0740697 (UMLS CUI [1])
Substance Dependence
Item
alcohol or drug dependence
boolean
C0038580 (UMLS CUI [1])
Hypersensitivity Sildenafil | Hypersensitivity Phosphodiesterase Inhibitors
Item
allergy or hypersensitivity to sildenafil or other phosphodiesterase inhibitors.
boolean
C0020517 (UMLS CUI [1,1])
C0529793 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0031638 (UMLS CUI [2,2])
C0529793 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0031638 (UMLS CUI [2,2])